Dishman dumps project to raise cash; Bedford recalls more products; Goldman invests in Orchid;

> Beleaguered Bedford Laboratories issued recall of a lot of Vecuronium Bromide after its was discovered some vials contain particulates. FDA announcement

> Goldman Sachs has acquired about a 1% stake in API maker Orchid Chemicals, paying Rs86m ($1.51 million) for 742,001 shares. Item

> With the results of an arrhythmia safety study in, the FDA is having GlaxoSmithKline ($GSK) expand the labeling changes on its Zofran, which is used in chemotherapy for vomiting and nausea. Story

> Ampio Pharmaceuticals, has contracted with Syngene in Bangalore, India, to begin manufacturing the products it now has in clinical trials. Release

> Survey finds increase in single-use technology for fill and finish. Story

> Standard Process is recalling its dietary supplements Cataplex ACP, Cataplex C and Pancreatrophin PMG, which are generally provided through doctors, after a routine inspection by the FDA discovered one of the ingredients in them may be contaminated with salmonella. FDA alert

And Finally... Dishman Pharmaceuticals is dumping its 6-year-old Special Economic Zone project near Ahmedabad, India, and will sell the land and use the proceeds to pay off debt. Story

Suggested Articles

A biotech that worked with a nutritional products maker on the API for its clinical-stage radiation drug, is buying all of the manufacturing know-how.

Merck KGaA is selling a manufacturing site and its Allergopharma allergy drug business as it focuses on newer meds.

In a first, the FDA and Indian oversight agencies worked together to block illegal drugs from entering the U.S.